- Home
- CATO vs RNXT Comparison
CATO vs RNXT Comparison
Compare CATO & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CATO
- RNXT
- Stock Information
- Founded
- CATO 1946
- RNXT 2012
- Country
- CATO United States
- RNXT United States
- Employees
- CATO N/A
- RNXT N/A
- Industry
- CATO Clothing/Shoe/Accessory Stores
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- CATO Consumer Discretionary
- RNXT Health Care
- Exchange
- CATO Nasdaq
- RNXT Nasdaq
- Market Cap
- CATO 55.7M
- RNXT 44.6M
- IPO Year
- CATO N/A
- RNXT 2021
- Fundamental
- Price
- CATO $2.56
- RNXT $1.40
- Analyst Decision
- CATO
- RNXT Strong Buy
- Analyst Count
- CATO 0
- RNXT 2
- Target Price
- CATO N/A
- RNXT $7.00
- AVG Volume (30 Days)
- CATO 43.9K
- RNXT 210.6K
- Earning Date
- CATO 05-22-2025
- RNXT 05-15-2025
- Dividend Yield
- CATO 13.28%
- RNXT N/A
- EPS Growth
- CATO N/A
- RNXT N/A
- EPS
- CATO N/A
- RNXT N/A
- Revenue
- CATO $642,949,000.00
- RNXT $240,000.00
- Revenue This Year
- CATO N/A
- RNXT $3,927.91
- Revenue Next Year
- CATO N/A
- RNXT $219.75
- P/E Ratio
- CATO N/A
- RNXT N/A
- Revenue Growth
- CATO N/A
- RNXT N/A
- 52 Week Low
- CATO $2.19
- RNXT $0.75
- 52 Week High
- CATO $6.70
- RNXT $1.69
- Technical
- Relative Strength Index (RSI)
- CATO 47.88
- RNXT 78.13
- Support Level
- CATO $2.50
- RNXT $1.17
- Resistance Level
- CATO $2.89
- RNXT $1.30
- Average True Range (ATR)
- CATO 0.19
- RNXT 0.08
- MACD
- CATO 0.01
- RNXT 0.02
- Stochastic Oscillator
- CATO 28.85
- RNXT 100.00
About CATO Cato Corporation (The)
The Cato Corp operates as a specialty retailer of fashion apparel and accessories in the southeastern United States. Its primary objective is to be the fashion specialty retailer for fashion and value in its markets. The company operates through the following business segments: Retail and Credit. The Retail segment which generates the majority of revenue offers fashion specialty stores. The Credit segment involves credit card services.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.